GIO Therapeutics
Nikki March is a highly experienced professional in the field of oncology and cancer research, currently serving as a Scientific Advisory Board Member at Carcinotech Ltd and as a Senior Director of Scientific Affairs at both GIO Therapeutics and Cumulus Oncology. Nikki's extensive background includes roles as a Cancer Biology Advisor with Edanz Oncology and a Scientific Consultant at CamScribe, alongside editorial positions at Edanz Group. Previously, Nikki held significant scientific leadership positions at Cancer Research UK Manchester Institute and Cambridge Institute, focusing on drug discovery, target validation, and cancer biology research. Academic credentials include a PhD in Cancer Biochemistry from the University of Cambridge and a BSc in Medical Biology from Brunel University London.
This person is not in any teams
This person is not in any offices
GIO Therapeutics
GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Recent scientific research has highlighted the crucial role of GPCRs as membrane receptors within the tumour microenvironment where their role significantly impacts intercellular signalling. This discovery has produced a new pool of potential therapeutic targets, which are now becoming accessible thanks to advanced structure-based drug design techniques. Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Each member of the GIO team brings a unique set of skills and experiences, all united by a shared passion for drug discovery and a history of building and creating successful companies. At GIO Therapeutics, we believe in the power of collaboration to drive innovation and achieve groundbreaking results in oncology. We welcome like-minded organisation and professionals to get in touch. GIO Therapeutics is a proud venture of Cumulus Oncology.